QSAR and pharmacophore modeling of N-acetyl-2-aminobenzothiazole class of phosphoinositide-3-kinase-α inhibitors

Medicinal Chemistry Research

Volumn 22, Issue 2, 2013, Pages 890-899

  Bharate, Sandip B ^a   Singh, Baljinder ^a   Bharate, Jaideep B ^a   Jain, Shreyans K ^a   Meena, Samdarshi ^a   Vishwakarma, Ram A ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Anticancer; Multiple regression analysis; N Acetyl 2 aminobenzothiazole; Partial least square analysis; Pharmacophore model; PI3K ; QSAR

Indexed keywords

N ACETYL 2 AMINOBENZOTHIAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG SCREENING; HYDROGEN BOND; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84873998021     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0081-3     Document Type: Article

References (26)

1. Abreu RMV, Ferreira ICFR, Queiroz MJRP (2009) QSAR model for predicting radical scavenging activity of di(hetero)arylamines derivatives of benzo[b]thiophenes. Eur J Med Chem 44:1952-1958
2. Bharate SB, Singh IP (2011) Quantitative structure-activity relationship study of phloroglucinol-terpene adducts as anti-leishmanial agents. Bioorg Med Chem Lett 21:4310-4315
3. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
4. D'Angelo ND, Kim T-S, Andrews K, Booker SK, Caenepeel S, Chen K, D'Amico D, Freeman D, Jiang J, Liu L, McCarter JD, Miguel TS, Mullady z EL, Schrag M, Subramanian R, Tang J, Wahl RC, Wang L, Whittington DA, Wu T, Xi N, Xu Y, Yakowec P, Yang K, Zalameda LP, Zhang N, Hughes P, Norman MH (2011) Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. J Med Chem 54:1789-1811
5. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006a) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647-671
6. Dixon SL, Smondyrev AM, Rao SN (2006b) PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 67:370-372
7. Drees BE, Mills GB, Rommel C, Prestwich GD (2004) Therapeutic potential of phosphoinositide 3-kinase inhibitors. Exp Opin Ther Patents 14:703-732
8. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22
9. Hall LH, Kier LB (1991) The molecular connectivity Chi indexes and Kappa shape indexes in structure-property relations. In: Boyd D, Lipkowitz K (eds) Reviews of computational chemistry. VCH Publishers, Inc., Lipkowitz, pp 367-422
10. Ihle NT, Powis G (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 8:1-9
11. JChem for Excel version 5.4.0.411 (2008-2010). ChemAxon Ltd. http://www.chemaxon.com
12. Kok K, Geering B, Vanhaesebroeck B (2009) Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 648:115-127
13. Kuruvilla FG, Schreiber SL (1999) The PIK-related kinases intercept conventional signaling pathways. Chem Biol 6:R129-R136
14. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644
15. Lohray BB, Gandhi N, Srivastava BK, Lohray VB (2006) 3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyl-oxazolidinones: a novel class of antibacterial agents. Bioorg Med Chem Lett 16:3817-3823
16. Nargotra A, Koul S, Sharma S, Khan IA, Kumar A, Thota N, Koul JL, Taneja SC, Qazi GN (2009) Quantitative structure-activity relationship (QSAR) of aryl alkenyl amides/imines for bacterial efflux pump inhibitors. Eur J Med Chem 44:229-238
17. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20:84-90
18. ®, Version 3.0.110, Maestro 8.5.111 (2009) Schrodinger, Inc., LLC, NewYork
19. Ramar S, Bag S, Tawari NR, Degani MS (2007) 3-D-QSAR analysis of 2-(oxalylamino) benzoic acid class of protein tyrosine phosphatase 1B inhibitors by CoMFA and Cerius2.GA. QSAR Comb Sci 26:608-617
20. Sharma H, Patil S, Sanchez TW, Neamati N, Schinazi RF, Buolamwini JK (2011) Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorg Med Chem 19:2030-2045
21. Stephens L, Williams R, Hawkins P (2005) Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 5:357-365
22. Strimpakos AS, Karapanagiotou EM, Saif WM, Syrigos KN (2009) The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35:148-159
23. Sun X, Huang J, Homma T, Kita D, Klocker H, Schafer G, Boyle P, Ohgaki H (2009) Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 29:1739-1744
24. Topliss JG, Costello RJ (1972) Chance correlations in structure-activity studies using multiple regression analysis. J Med Chem 15:1066-1068
25. ® (2000) Oxford Molecular Ltd. http://www.accelrys.com
26. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501